Search

Your search keyword '"Conticello, Concetta"' showing total 520 results
Start Over Author "Conticello, Concetta"
520 results on '"Conticello, Concetta"'

1. Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience

Author

Mele, Giuseppe, Derudas, Daniele, Conticello, Concetta, Barilà, Gregorio, Gentile, Massimo, Rocco, Stefano, Palmieri, Salvatore, Palazzo, Giulia, Germano, Candida, Reddiconto, Giovanni, Sgherza, Nicola, De Novellis, Danilo, Galeone, Carlotta, Castiglioni, Sara Agavni’, Deiana, Luca, Pascarella, Anna, Martino, Enrica Antonia, Foggetti, Ilaria, Blasi, Ilenia, Spina, Alessandro, Di Renzo, Nicola, Maggi, Alessandro, Tarantini, Giuseppe, Di Raimondo, Francesco, Specchia, Giorgina, Musto, Pellegrino, and Pastore, Domenico

Published
2024
Full Text
View/download PDF

2. CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment

Author

Giallongo, Cesarina, Dulcamare, Ilaria, Tibullo, Daniele, Del Fabro, Vittorio, Vicario, Nunzio, Parrinello, Nunziatina, Romano, Alessandra, Scandura, Grazia, Lazzarino, Giacomo, Conticello, Concetta, Li Volti, Giovanni, Amorini, Angela Maria, Musumeci, Giuseppe, Di Rosa, Michelino, Polito, Francesca, Oteri, Rosaria, Aguennouz, M’hammed, Parenti, Rosalba, Di Raimondo, Francesco, and Palumbo, Giuseppe A.

Published
2022
Full Text
View/download PDF

3. IgG-k/IgG-λ Para-Osseous Plasmacytoma Relapsed as Soft-Tissue Plasmacytoma with IgA-k Immunophenotype: A Case Report and Review of the Literature on Related Biochemical Aspects.

Author

Fazio, Manlio, Sorbello, Chiara Maria Catena, Del Fabro, Vittorio, Romano, Alessandra, Cannizzaro, Maria Teresa, Parrinello, Nunziatina Laura, Esposito, Benedetta, Frazzetto, Sara, Elia, Federica, Di Raimondo, Francesco, and Conticello, Concetta

Subjects
EXTRAMEDULLARY diseases, IMMUNOGLOBULIN light chains, LITERATURE reviews, PLASMA cells, COMPACT bone, PLASMACYTOMA
Abstract

Neoplastic plasma cells (PCs) proliferation at anatomic sites dislocated from the bone marrow (BM) or their contiguous growth from osseous lesions that disrupt the cortical bone is termed extramedullary multiple myeloma (EMD). EMD still remains challenging from a therapeutic and biological perspective. Pathogenesis has not been completely clarified, and it is generally associated with high-risk cytogenetics (HRCAs). In order to emphasize the clinical and biochemical complexity of this disease, we have decided to describe the case of a patient affected by relapsed-refractory (RR) EMD, which presented as para-osseous plasmacytoma with a bi-phenotypical immunoglobulin (Ig) component and lately relapsed as soft-tissue plasmacytoma with a total immunophenotype switch. We have also hypothesized a correlation between Ig patterns and prognosis and suggested the possible inclusion of these biochemical features in the general risk assessment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network.

Author

Del Fabro, Vittorio, Markovic, Uros, Frazzetto, Sara, Sciortino, Roberta, Bellofiore, Claudia, Di Giorgio, Mary Ann, Leotta, Valerio, Bulla, Anna, Curto Pelle, Angelo, Elia, Federica, Mannina, Donato, Consoli, Ugo, Mineo, Giuseppe, Giallongo, Cesarina, Romano, Alessandra, Di Raimondo, Francesco, and Conticello, Concetta

Published
2024
Full Text
View/download PDF

5. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.

Author

Condorelli, Annalisa, Garibaldi, Bruno, Gagliano, Caterina, Romano, Alessandra, Del Fabro, Vittorio, Parrinello, Nunziatina Laura, Longo, Antonio, Cosentino, Sebastiano, Di Raimondo, Francesco, and Conticello, Concetta

Subjects
CLINICAL trials, OCULAR toxicology, MULTIPLE myeloma, ANTIBODY-drug conjugates, MICROTUBULES
Abstract

Although the therapeutic landscape for multiple myeloma (MM) has expanded, the disease always tends to relapse. In an attempt to obtain deep and durable responses, each relapse requires the use of a new strategy. In recent years, new treatment options have emerged, even for heavily treated patients. Novel, well-tolerated, and highly effective therapies in the relapsed/refractory (RRMM) setting currently represent a real hope. Belantamab mafodotin (BLENREP™) is a first-in-class monoclonal antibody-drug conjugate whose target is B-cell maturation antigen conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin F. Here, we present two cases of heavily pre-treated RRMM patients that were favorably treated with belantamab mafodotin, obtaining at least a partial response. Treatment was well tolerated and is ongoing. This is a rare report on real life clinical use of belantamab mafodotin outside of controlled clinical trials and provides information on efficacy and safety of this anti-myeloma new class of drugs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials.

Author

Martino, Enrica Antonia, Palmieri, Salvatore, Galli, Monica, Derudas, Daniele, Mina, Roberto, Della Pepa, Roberta, Zambello, Renato, Vigna, Ernesto, Bruzzese, Antonella, Mangiacavalli, Silvia, Zamagni, Elena, Califano, Catello, Musso, Maurizio, Conticello, Concetta, Cerchione, Claudio, Mele, Giuseppe, Di Renzo, Nicola, Offidani, Massimo, Tarantini, Giuseppe, and Casaluci, Gloria Margiotta

Subjects
CLINICAL trials, MULTIPLE myeloma, DEXAMETHASONE, OVERALL survival, PROGRESSION-free survival
Abstract

The ELOQUENT‐3 trial demonstrated the superiority of the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) in terms of efficacy and safety, compared to Pd in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The present study is an 18‐month follow‐up update of a previously published Italian real‐life RRMM cohort of patients treated with EloPd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow‐up of 17.7 months, 213 patients (66.4%) experienced disease progression or died. Median progression‐free survival (PFS) and overall survival (OS) were 7.5 and 19.2 months, respectively. The updated multivariate analysis showed a significant reduction of PFS benefit magnitude both in advanced International Staging System (ISS) (II and III) stages and previous exposure to daratumumab cases. Instead, advanced ISS (II and III) stages and more than 2 previous lines of therapy maintained an independent prognostic impact on OS. Major adverse events included grade three‐fourths neutropenia (24.9%), anemia (13.4%), lymphocytopenia (15.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 19.3% and 8.7%, respectively. A slight increase in the incidence of neutropenia and lymphocytopenia was registered with longer follow‐up. In conclusion, our real‐world study still confirms that EloPd is a safe and possible therapeutic choice for RRMM. Nevertheless, novel strategies are desirable for those patients exposed to daratumumab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

Author

Bellofiore, Claudia, Benvenuti, Pietro, Mina, Roberto, Basset, Marco, Foli, Andrea, Nanci, Martina, Nuvolone, Mario, Guida, Gianluigi, Attanasio, Andrea, Mussinelli, Roberta, Mangiacavalli, Silvia, Cartia, Claudio Salvatore, Masoni, Valeria, Palumbo, Michele, Cani, Lorenzo, Oliva, Stefania, Consoli, Ugo, Conticello, Concetta, Di Raimondo, Francesco, and Arcaini, Luca

Subjects
DARATUMUMAB, AMYLOIDOSIS, LENALIDOMIDE, MULTIPLE myeloma, BORTEZOMIB
Abstract

Daratumumab‐based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real‐world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%). The rate of serious adverse events was low (16%). The overall hematologic response rate was 75% with 52 (59%) patients attaining at least a very good partial response (VGPR) at six months. Amongst patients evaluable for organ response, the rate of cardiac and renal responses at 6 months was 31% and 21%, respectively. Comparing stage IIIb patients with the remaining ones, the rate of profound hematologic response was not significantly different (≥VGPR 57% vs. 59%, p 0.955) likewise the rate of cardiac (33% vs. 30%, p 0.340) and renal (40% vs. 16%, p 0.908) responses. Daratumumab‐based regimens demonstrated to be safe and effective in treatment‐naïve AL amyloidosis even in advanced stage disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Belantamab mafodotin in triple‐refractory multiple myeloma patients: A retro‐prospective observational study in Italy.

Author

Fazio, Francesca, Petrucci, Maria Teresa, Corvatta, Laura, Piciocchi, Alfonso, Pepa, Roberta Della, Tacchetti, Paola, Musso, Maurizio, Zambello, Renato, Belotti, Angelo, Bringhen, Sara, Antonioli, Elisabetta, Conticello, Concetta, Renzo, Nicola Di, De Stefano, Valerio, Musto, Pellegrino, Gamberi, Barbara, Derudas, Daniele, Boccadoro, Mario, Offidani, Massimo, and Morè, Sonia

Published
2024
Full Text
View/download PDF

9. Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost

Author

Milone, Giuseppe, Conticello, Concetta, Leotta, Salvatore, Michieli, Maria Grazia, Martino, Massimo, Marco, Anna Lia Di, Spadaro, Andrea, Cupri, Alessandra, Condorelli, Annalisa, Milone, Giulio Antonio, Markovic, Uros, Sciortino, Roberta, Schininà, Giovanni, Moschetti, Gaetano, Villari, Loredana, and Saccardi, Riccardo

Published
2020
Full Text
View/download PDF

10. Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

Author

D’Agostino, Mattia, De Paoli, Lorenzo, Conticello, Concetta, Offidani, Massimo, Ria, Roberto, Petrucci, Maria Teresa, Spada, Stefano, Marcatti, Magda, Catalano, Lucio, Gilestro, Milena, Guglielmelli, Tommasina, Baldini, Luca, Gamberi, Barbara, Rizzi, Rita, De Sabbata, Giovanni, Di Renzo, Nicola, Patriarca, Francesca, Pezzatti, Sara, Siniscalchi, Agostina, Ribolla, Rossella, Palumbo, Antonio, Montefusco, Vittorio, Nagler, Arnon, Boccadoro, Mario, and Gay, Francesca

Published
2018
Full Text
View/download PDF

11. Multiple Myeloma in 2023 Ways: From Trials to Real Life

Author

Fazio, Manlio, primary, Del Fabro, Vittorio, additional, Parrinello, Nunziatina Laura, additional, Allegra, Alessandro, additional, Markovic, Uroš, additional, Botta, Cirino, additional, Accardi, Fabrizio, additional, Vincelli, Iolanda Donatella, additional, Leotta, Salvatore, additional, Elia, Federica, additional, Esposito, Benedetta, additional, Garibaldi, Bruno, additional, Sapuppo, Gabriele, additional, Orofino, Alessandra, additional, Romano, Alessandra, additional, Palumbo, Giuseppe A., additional, Di Raimondo, Francesco, additional, and Conticello, Concetta, additional

Published
2023
Full Text
View/download PDF

12. IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

Author

Duminuco, Andrea, primary, Nardo, Antonella, additional, Orofino, Alessandra, additional, Giunta, Giuliana, additional, Conticello, Concetta, additional, Del Fabro, Vittorio, additional, Figuera, Amalia, additional, Chiarenza, Annalisa, additional, Milone, Giuseppe, additional, Leotta, Salvatore, additional, Cupri, Alessandra, additional, Parisi, Marina, additional, Mauro, Elisa, additional, Vetro, Calogero, additional, Di Raimondo, Francesco, additional, Romano, Alessandra, additional, and Palumbo, Giuseppe A., additional

Published
2023
Full Text
View/download PDF

13. Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions

Author

Duminuco, Andrea, primary, Nardo, Antonella, additional, Orofino, Alessandra, additional, Giunta, Giuliana, additional, Conticello, Concetta, additional, Del Fabro, Vittorio, additional, Chiarenza, Annalisa, additional, Parisi, Marina S., additional, Figuera, Amalia, additional, Leotta, Salvatore, additional, Milone, Giuseppe, additional, Cupri, Alessandra, additional, Cambria, Daniela, additional, Di Raimondo, Francesco, additional, Romano, Alessandra, additional, and Palumbo, Giuseppe A., additional

Published
2023
Full Text
View/download PDF

14. P-325 Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials

Author

Weisel, Katja, primary, Mateos, Maria-Victoria, additional, Garcia, Maria Esther Gonzalez, additional, Bittrich, Max, additional, Lindsey-Hill, Joanne, additional, De Stefano, Valerio, additional, Besemer, Britta, additional, Vincent, Laure, additional, Kirkpatrick, Suriya, additional, Karlin, Lionel, additional, Goldschmidt, Hartmut, additional, Conticello, Concetta, additional, Roeloffzen, Wilfried, additional, van de Donk, Niels, additional, Delforge, Michel, additional, Doyle, Margaret, additional, Gray, Kathleen, additional, Albrecht, Claire, additional, Strulev, Vadim, additional, Haddad, Imène, additional, Saarinen, Silva, additional, Mitchell, Lada, additional, Buyze, Jozefien, additional, and Moreau, Philippe, additional

Published
2023
Full Text
View/download PDF

15. POSTER: IBCL-057 Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis

Author

Duminuco, Andrea, primary, Nardo, Antonella, additional, Orofino, Alessandra, additional, Giunta, Giuliana, additional, Conticello, Concetta, additional, Del Fabro, Vittorio, additional, Figuera, Amalia, additional, Chiarenza, Annalisa, additional, Milone, Giuseppe, additional, Leotta, Salvatore, additional, Cupri, Alessandra, additional, Parisi, Marina, additional, Mauro, Elisa, additional, Vetro, Calogero, additional, Di Raimondo, Francesco, additional, Romano, Alessandra, additional, and Palumbo, Giuseppe A., additional

Published
2023
Full Text
View/download PDF

16. Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study)

Author

Musto, Pellegrino, Simeon, Vittorio, Cascavilla, Nicola, Falcone, Antonietta, Petrucci, Maria Teresa, Cesini, Laura, Di Raimondo, Francesco, Conticello, Concetta, Ria, Roberto, Catalano, Lucio, Salvatore, Dalila, Mastrullo, Lucia, Gagliardi, Alfredo, Villani, Oreste, Pietrantuono, Giuseppe, D’Arena, Giovanni, Mansueto, Giovanna, Bringhen, Sara, Genuardi, Mariella, Di Renzo, Nicola, Reddiconto, Giovanni, Fragasso, Alberto, Caravita, Tommaso, Scapicchio, Daniele, Marziano, Gioacchino, Boccadoro, Mario, Mangiacavalli, Silvia, and Corso, Alessandro

Published
2019
Full Text
View/download PDF

17. Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study

Author

Del Fabro, Vittorio, primary, Di Giorgio, Mary Ann, additional, Leotta, Valerio, additional, Duminuco, Andrea, additional, Bellofiore, Claudia, additional, Markovic, Uros, additional, Romano, Alessandra, additional, Bulla, Anna, additional, Curto Pelle, Angelo, additional, Elia, Federica, additional, Di Raimondo, Francesco, additional, and Conticello, Concetta, additional

Published
2023
Full Text
View/download PDF

18. P895: DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION: UPDATED ANALYSIS OF THE DEDALO PHASE II TRIAL

Author

Montefusco, Vittorio, primary, Maria Cafro, Anna, additional, Margiotta-Casaluci, Gloria, additional, Patriarca, Francesca, additional, Mina, Roberto, additional, D’agostino5, Mattia, additional, Palma, Anna Benedetta Dalla, additional, Rizzi, Rita, additional, Genua, Angelo, additional, Fazio, Francesca, additional, Paris, Laura, additional, Belotti, Angelo, additional, Rizzello, Ilaria, additional, Conticello, Concetta, additional, Carlo-Stella, Carmelo, additional, and Boccadoro, Mario, additional

Published
2023
Full Text
View/download PDF

21. P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS

Author

Duminuco, Andrea, primary, Nardo, Antonella, additional, Orofino, Alessandra, additional, Romano, Alessandra, additional, Figuera, Amalia Stefania, additional, Chiarenza, Annalisa, additional, Markovic, Uros, additional, Caruso, Laura, additional, Giunta, Giuliana, additional, Leotta, Salvatore, additional, Milone, Giuseppe, additional, Cupri, Alessandra, additional, Conticello, Concetta, additional, Fabro, Vittorio Del, additional, Mauro, Elisa, additional, Maugeri, Cinzia, additional, Vetro, Calogero, additional, Parisi, Marina, additional, Raimondo, Francesco DI, additional, and Palumbo, Giuseppe, additional

Published
2023
Full Text
View/download PDF

22. P852: ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS

Author

Romano, Alessandra, primary, Scandura, Grazia, additional, Giallongo, Cesarina, additional, La Spina, Enrico, additional, Longhitano, Lucia, additional, Zuppelli, Tatiana, additional, Dulcamare, Ilaria, additional, Laura Parrinello, Nunziatina, additional, Polito, Francesca, additional, Oteri, Rosaria, additional, Aguennouz, Mohammed, additional, Vicario, Nunzio, additional, Maria Amorini, Angela, additional, Del Fabro, Vittorio, additional, Conticello, Concetta, additional, Volti, Giovanni LI, additional, Alberto Palumbo, Giuseppe, additional, Tibullo, Daniele, additional, and Raimondo, Francesco DI, additional

Published
2023
Full Text
View/download PDF

23. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials

Author

Gentile, Massimo, primary, Vigna, Ernesto, additional, Palmieri, Salvatore, additional, Galli, Monica, additional, Derudas, Daniele, additional, Mina, Roberto, additional, Pepa, Roberta Della, additional, Zambello, Renato, additional, Martino, Enrica Antonia, additional, Bruzzese, Antonella, additional, Mangiacavalli, Silvia, additional, Zamagni, Elena, additional, Califano, Catello, additional, Musso, Maurizio, additional, Conticello, Concetta, additional, Cerchione, Claudio, additional, Mele, Giuseppe, additional, Di Renzo, Nicola, additional, Offidani, Massimo, additional, Tarantini, Giuseppe, additional, Casaluci, Gloria Margiotta, additional, Rago, Angela, additional, Ria, Roberto, additional, Uccello, Giuseppina, additional, Barilà, Gregorio, additional, Palumbo, Gaetano, additional, Pompa, Alessandra, additional, Vincelli, Donatella, additional, Brunori, Marino, additional, Accardi, Fabrizio, additional, Amico, Valeria, additional, Amendola, Angela, additional, Fontana, Raffaele, additional, Bongarzoni, Velia, additional, Rossini, Bernardo, additional, Cotzia, Emilia, additional, Gozzetti, Alessandro, additional, Rizzi, Rita, additional, Sgherza, Nicola, additional, Ferretti, Eleonora, additional, Bertuglia, Giuseppe, additional, Nappi, Davide, additional, Petrucci, Maria Teresa, additional, Di Raimondo, Francesco, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Musto, Pellegrino, additional

Published
2023
Full Text
View/download PDF

24. Efficacy and safety of tixagevimab‐cilgavimab versus SARS‐CoV‐2 breakthrough infection in the hematological conditions.

Author

Duminuco, Andrea, Nardo, Antonella, Orofino, Alessandra, Giunta, Giuliana, Conticello, Concetta, Del Fabro, Vittorio, Chiarenza, Annalisa, Parisi, Marina S., Figuera, Amalia, Leotta, Salvatore, Milone, Giuseppe, Cupri, Alessandra, Cambria, Daniela, Di Raimondo, Francesco, Romano, Alessandra, and Palumbo, Giuseppe A.

Subjects
BREAKTHROUGH infections, BLOOD diseases, SARS-CoV-2, MONOCLONAL antibodies, BONE marrow
Abstract

Background: Managing SARS‐CoV‐2 infection in frail and immunosuppressed patients still represents an open challenge, but, starting from the phase 3 PROVENT study, prophylaxis with tixagevimab‐cilgavimab has improved the approach in this category of patients, guaranteeing a better outcome and inferior mortality. Real‐life data in a heterogeneous cohort are few. Methods: The aim of this study is to evaluate the benefit of prophylaxis with tixagevimab‐cilgavimab in a cohort of 202 patients affected by different hematological diseases (lymphoproliferative, myeloproliferative, autoimmune, patients recently receiving a bone marrow transplant), active (with ongoing treatment), or in watch‐and‐wait strategy, followed in our center, during a median follow‐up of 249 (45‐325) days. Results: An incidence of 44 breakthrough infections (21.8%) is reported, with no treatment‐related adverse effects. Age ≥70 years, ongoing treatment (above all with monoclonal antibodies), baseline lymphoproliferative disorders, and prior virus exposure are identified as risk factors related to subsequent infection (p < 0.05). Moreover, the incidence is higher in low/nonresponse to prior vaccination (p =.002). Patients treated with tixagevimab‐cilgavimab had a mild course of the infection and a reduction of the duration compared with preprophylaxis infection (11 vs. 15 days, p <.001). The concurrent treatment with anti‐CD20 monoclonal antibodies and B–non‐Hodgkin lymphoma still confers a higher duration of infection despite prophylaxis. No deaths attributable to the infection occurred. Conclusion: Prophylaxis treatment seems to be a valid and safe strategy, although not preventing breakthrough infection, but the severe complications associated with the infection and the possible delays in administering lifesaving therapies from long positivity. The use of tixagevimab‐cilgavimab improved the management of immunocompromised patients with a high risk of severe SARS‐CoV‐2 disease. In a real‐world setting, it confirmed its role not only in preventing the occurrence of breakthrough infection, but also, above all, avoiding the severe complications associated and reducing the total days of positivity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.

Author

Giuffrida, Gaetano, Markovic, Uros, Condorelli, Annalisa, Duminuco, Andrea, Calafiore, Valeria, Conticello, Concetta, Romano, Alessandra, Grasso, Stephanie, Riccobene, Carla, Ragusa, Marco Tindaro Valentino, Esposito, Benedetta, Nicolosi, Daniela, Calagna, Marianna, Nardo, Antonella, Consoli, Ugo, Uccello, Giuseppina, Di Giacomo, Valeria, Neri, Santo, Cingari, Maria Rocca, and Rodà, Filippo

Subjects
GLYCOGEN storage disease type II, MONOCLONAL gammopathies, GAUCHER'S disease, DISEASE prevalence, LYSOSOMAL storage diseases, PATIENT experience, DELAYED diagnosis
Abstract

Background: Gaucher disease (GD) is a rare autosomal recessive inherited disorder caused by the lysosomal enzyme acid β‐glucosidase deficiency. Many patients experience a critical delay in the diagnosis of up to 8–10 years due to its rarity and variability in signs and symptoms, with the consultation of several specialists. Patients and Methods: This prospective observational study analyzed the prevalence of GD in 600 patients with monoclonal gammopathy of uncertain significance (MGUS) from January 2018 until February 2022. Results: The mean age of participants was 66 years, with a mean monoclonal component of 0.58 g/dL. In 433 MGUS patients with available data, anemia (hemoglobin level < 10 g/dL) was present in 31 patients (7%), and thrombocytopenia (platelet count <100.000/mm3) in 24 (5.5%). Of 600 MGUS patients tested for acid β‐glucosidase enzyme activity, 7 patients (1.2%) had activity below 2.5 nmol/h/mL. In comparison, GBA gene analysis was executed in 110 patients. It revealed 4 patients (0.7%) affected by GD (3 patients with compound heterozygous mutation and 1 with homozygous mutation), with a prevalence of 1 every 150 MGUS patients. Furthermore, 12 out of the remaining 106 evaluated patients (11%) were carriers of a single heterozygous mutation while having regular enzyme activity. Conclusions: The clinical heterogeneity of GD and frequent lack of awareness among physicians often lead to diagnostic delays and severe clinical manifestations. The role of MGUS in the presence of at least one clinical sign, such as low platelet count, organomegaly, bone pain, or bleeding tendency, could aid in initiating GD screening with DBS, thus reducing the period between symptom onset and the diagnosis of this rare disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab

Author

Duminuco, Andrea, primary, Romano, Alessandra, additional, Leotta, Dario, additional, La Spina, Enrico, additional, Cambria, Daniela, additional, Bulla, Anna, additional, Del Fabro, Vittorio, additional, Tibullo, Daniele, additional, Giallongo, Cesarina, additional, Palumbo, Giuseppe A., additional, Conticello, Concetta, additional, and Di Raimondo, Francesco, additional

Published
2023
Full Text
View/download PDF

28. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Author

Magarotto, Valeria, Bringhen, Sara, Offidani, Massimo, Benevolo, Giulia, Patriarca, Francesca, Mina, Roberto, Falcone, Antonietta Pia, De Paoli, Lorenzo, Pietrantuono, Giuseppe, Gentili, Silvia, Musolino, Caterina, Giuliani, Nicola, Bernardini, Annalisa, Conticello, Concetta, Pulini, Stefano, Ciccone, Giovannino, Maisnar, Vladimír, Ruggeri, Marina, Zambello, Renato, Guglielmelli, Tommasina, Ledda, Antonio, Liberati, Anna Marina, Montefusco, Vittorio, Hajek, Roman, Boccadoro, Mario, and Palumbo, Antonio

Published
2016
Full Text
View/download PDF

29. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Author

Gay, Francesca, Oliva, Stefania, Petrucci, Maria Teresa, Conticello, Concetta, Catalano, Lucio, Corradini, Paolo, Siniscalchi, Agostina, Magarotto, Valeria, Pour, Luděk, Carella, Angelo, Malfitano, Alessandra, Petrò, Daniela, Evangelista, Andrea, Spada, Stefano, Pescosta, Norbert, Omedè, Paola, Campbell, Philip, Liberati, Anna Marina, Offidani, Massimo, Ria, Roberto, Pulini, Stefano, Patriarca, Francesca, Hajek, Roman, Spencer, Andrew, Boccadoro, Mario, and Palumbo, Antonio

Published
2015
Full Text
View/download PDF

30. Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma

Author

Giallongo, Cesarina, Tibullo, Daniele, Camiolo, Giuseppina, Parrinello, Nunziatina L., Romano, Alessandra, Puglisi, Fabrizio, Barbato, Alessandro, Conticello, Concetta, Lupo, Gabriella, Anfuso, Carmelina Daniela, Lazzarino, Giacomo, Volti, Giovanni Li, Palumbo, Giuseppe Alberto, and Di Raimono, Francesco

Published
2019
Full Text
View/download PDF

32. Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Author

Montefusco, Vittorio, primary, Cafro, Anna Maria, additional, Margiotta Casaluci, Gloria, additional, Patriarca, Francesca, additional, Mina, Roberto, additional, D'Agostino, Mattia, additional, Capra, Andrea, additional, Priola, Claudia, additional, Dalla Palma, Anna Benedetta, additional, Rizzi, Rita, additional, Genua, Angelo, additional, Petrucci, Maria Teresa, additional, Paris, Laura, additional, Belotti, Angelo, additional, Cavo, Michele, additional, Conticello, Concetta, additional, Carlo-Stella, Carmelo, additional, and Boccadoro, Mario, additional

Published
2022
Full Text
View/download PDF

33. Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

Author

Gelli, Elisa, primary, Laudisi, Antonella, additional, Martinuzzi, Claudia, additional, Soncini, Debora, additional, Becherini, Pamela, additional, Guolo, Fabio, additional, Conticello, Concetta, additional, Derudas, Daniele, additional, Di Raimondo, Francesco, additional, Cagnetta, Antonia, additional, Coviello, Domenico, additional, Lemoli, Roberto Massimo, additional, and Cea, Michele, additional

Published
2022
Full Text
View/download PDF

36. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

Author

Morabito, Fortunato, primary, Zamagni, Elena, additional, Conticello, Concetta, additional, Pavone, Vincenzo, additional, Palmieri, Salvatore, additional, Bringhen, Sara, additional, Galli, Monica, additional, Mangiacavalli, Silvia, additional, Derudas, Daniele, additional, Rossi, Elena, additional, Ria, Roberto, additional, Catalano, Lucio, additional, Tacchetti, Paola, additional, Mele, Giuseppe, additional, Vincelli, Iolanda Donatella, additional, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Bruzzese, Antonella, additional, Mendicino, Francesco, additional, Botta, Cirino, additional, Mele, Anna, additional, Pantani, Lucia, additional, Rocchi, Serena, additional, Garibaldi, Bruno, additional, Cascavilla, Nicola, additional, Ballanti, Stelvio, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Falcone, Antonetta Pia, additional, Cangialosi, Clotilde, additional, Reddiconto, Giovanni, additional, Farina, Giuliana, additional, Barone, Marialucia, additional, Rizzello, Ilaria, additional, Iaccino, Enrico, additional, Mimmi, Selena, additional, Curci, Paola, additional, Gamberi, Barbara, additional, Musto, Pellegrino, additional, De Stefano, Valerio, additional, Musso, Maurizio, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Di Raimondo, Francesco, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Neri, Antonino, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

37. Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

Author

Botta, Cirino, primary, Gigliotta, Emilia, additional, Paiva, Bruno, additional, Anselmo, Rita, additional, Santoro, Marco, additional, Otero, Paula Rodriguez, additional, Carlisi, Melania, additional, Conticello, Concetta, additional, Romano, Alessandra, additional, Solimando, Antonio Giovanni, additional, Cerchione, Claudio, additional, Vià, Matteo Da, additional, Bolli, Niccolò, additional, Correale, Pierpaolo, additional, Di Raimondo, Francesco, additional, Gentile, Massimo, additional, San Miguel, Jesus, additional, and Siragusa, Sergio, additional

Published
2022
Full Text
View/download PDF

38. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Author

Bruzzese, Antonella, primary, Derudas, Daniele, additional, Galli, Monica, additional, Martino, Enrica Antonia, additional, Rocco, Stefano, additional, Conticello, Concetta, additional, Califano, Catello, additional, Giuliani, Nicola, additional, Mangiacavalli, Silvia, additional, Farina, Giuliana, additional, Lombardo, Alessandra, additional, Brunori, Marino, additional, Rossi, Elena, additional, Antonioli, Elisabetta, additional, Ria, Roberto, additional, Zambello, Renato, additional, Di Renzo, Nicola, additional, Mele, Giuseppe, additional, Marcacci, Gianpaolo, additional, Pietrantuono, Giuseppe, additional, Palumbo, Gaetano, additional, Cascavilla, Nicola, additional, Cerchione, Claudio, additional, Belotti, Angelo, additional, Criscuolo, Clelia, additional, Uccello, Giuseppina, additional, Curci, Paola, additional, Vigna, Ernesto, additional, Mendicino, Francesco, additional, Iaccino, Enrico, additional, Mimmi, Selena, additional, Botta, Cirino, additional, Vincelli, Donatella, additional, Sgherza, Nicola, additional, Bonalumi, Angela, additional, Cupelli, Luca, additional, Stocchi, Raffaella, additional, Martino, Massimo, additional, Ballanti, Stelvio, additional, Gangemi, Dominella, additional, Gagliardi, Alfredo, additional, Gamberi, Barbara, additional, Pompa, Alessandra, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Consoli, Ugo, additional, Bringhen, Sara, additional, Zamagni, Elena, additional, Patriarca, Francesca, additional, De Stefano, Valerio, additional, Di Raimondo, Francesco, additional, Palmieri, Salvatore, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

40. Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection

Author

Romano, Alessandra, primary, Cerchione, Claudio, additional, Conticello, Concetta, additional, Filetti, Sabina, additional, Bulla, Anna, additional, Chiarenza, Annalisa, additional, Del Fabro, Vittorio, additional, Leotta, Salvatore, additional, Markovic, Uros, additional, Motta, Giovanna, additional, Parisi, Marina, additional, Stagno, Fabio, additional, Palumbo, Giuseppe Alberto, additional, and Di Raimondo, Francesco, additional

Published
2022
Full Text
View/download PDF

41. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.

Author

Martino, Enrica Antonia, Conticello, Concetta, Zamagni, Elena, Pavone, Vincenzo, Palmieri, Salvatore, Musso, Maurizio, Tacchetti, Paola, Mele, Anna, Catalano, Lucio, Vigna, Ernesto, Bruzzese, Antonella, Mendicino, Francesco, Botta, Cirino, Vincelli, Iolanda Donatella, Farina, Giuliana, Barone, Marialucia, Cangialosi, Clotilde, Mancuso, Katia, Rizziello, Ilaria, and Rocchi, Serena

Subjects
MULTIPLE myeloma, CLINICAL trials, SALVAGE therapy, LENALIDOMIDE, PROGRESSION-free survival, ARRHYTHMIA, HEART failure
Abstract

In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet are still the object of investigation by many groups to confirm ASPIRE results in the setting of RRMM treated in real‐life who don't meet trial restrictive inclusion criteria. Therefore, we report a retrospective multicenter analysis of 600 RRMM patients treated with KRd between December 2015 and December 2018. The median age was 64 years (range 33–85), and the median number of previous therapies was two (range 1–11). After a median of 11 KRd cycles, the overall response rate was 79.9%. The median progression‐free survival (PFS) was 22 months, and the 2‐year probability of PFS was 47.6%. Creatinine clearance<30 ml/min, >1 line of previous therapy, and high‐risk FISH were all associated with a poor prognosis in multivariate analysis. The median overall survival (OS) was 34.8 months; the 2‐year probability of OS was 63.5%. At multivariate analysis, creatinine clearance<30 ml/min, >1 line of previous therapy, and high‐risk FISH were significantly associated with poor prognosis. After a median follow‐up of 16 months (range 1–50), 259 withdrew from therapy. The main discontinuation reason was progressive disease (81.8%). Seventy‐four patients (12.3%) discontinued therapy for toxicity. The most frequent side effects were hematological (anemia 49.3%, neutropenia 42.7%, thrombocytopenia 42.5%) and cardiovascular (hypertension 14.5%, heart failure 2.5%, arrhythmias 3.6%). Our study confirms the safety and efficacy of KRd in the real‐life setting of RRMM patients and encourages its use in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients

Author

Morabito, Fortunato, primary, Zamagni, Elena, additional, Conticello, Concetta, additional, Pavone, Vincenzo, additional, Palmieri, Salvatore, additional, Bringhen, Sara, additional, Galli, Monica, additional, Mangiacavalli, Silvia, additional, Derudas, Daniele, additional, Rossi, Elena, additional, Ria, Roberto, additional, Catalano, Lucio, additional, Tacchetti, Paola, additional, Mele, Giuseppe, additional, Donatella Vincelli, Iolanda, additional, Antonia Martino, Enrica, additional, Vigna, Ernesto, additional, Botta, Cirino, additional, Bruzzese, Antonella, additional, Mele, Anna, additional, Pantani, Lucia, additional, Rocchi, Serena, additional, Garibaldi, Bruno, additional, Cascavilla, Nicola, additional, Ballanti, Stelvio, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Pia Falcone, Antonetta, additional, Cangialosi, Clotilde, additional, Reddiconto, Giovanni, additional, Farina, Giuliana, additional, Barone, Marialucia, additional, Rizzello, Ilaria, additional, Musto, Pellegrino, additional, De Stefano, Valerio, additional, Musso, Maurizio, additional, Teresa Petrucci, Maria, additional, Offidani, Massimo, additional, Neri, Antonino, additional, Di Renzo, Nicola, additional, Di Raimondo, Francesco, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

45. CXCL12/CXCR4 Axis Drives Mitochondrial Trafficking in Tumor Myeloma Microenvironment

Author

Giallongo, Cesarina, primary, Dulcamare, Ilaria, additional, Tibullo, Daniele, additional, Del Fabro, Vittorio, additional, Vicario, Nunzio, additional, Parrinello, Nunziatina Laura, additional, Romano, Alessandra, additional, Scandura, Grazia, additional, Barbato, Alessandro, additional, La Spina, Enrico, additional, Cambria, Daniela, additional, Lazzarino, Giacomo, additional, Conticello, Concetta, additional, Li Volti, Giovanni, additional, Musumeci, Giuseppe, additional, Palumbo, Giuseppe A., additional, and Di Raimondo, Francesco, additional

Published
2021
Full Text
View/download PDF

48. Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Author

Barila, Gregorio, Grassi, Angela, Conticello, Concetta, Mina, Roberto, Marcon, Chiara, Fazio, Francesca, Cartia, Claudio Salvatore, Tinelli, Martina, Del Giudice, Maria Livia, Pilerci, Sofia, Belotti, Angelo, Pascarella, Anna, Tafuri, Mariantonietta, Rocchi, Serena, Sgherza, Nicola, Mele, Giuseppe, Scomazzon, Edoardo, Gentile, Massimo, Porrazzo, Marika, Pescosta, Norbert, Furlan, Anna, Febbo, Massimiliano Arangio, Clissa, Cristina, Casson, Andrea, Ribolla, Rossella, Maroccia, Antonio, Lisi, Chiara, Martino, Enrica Antonia, Annibali, Ombretta, Buda, Gabriele, Antonioli, Elisabetta, Mangiacavalli, Silvia, Tosetto, Alberto, Musto, Pellegrino, Gay, Francesca, Zamagni, Elena, Petrucci, Maria Teresa, Di Raimondo, Francesco, Patriarca, Francesca, and Zambello, Renato

Published
2023
Full Text
View/download PDF

49. Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Author

Mangiacavalli, Silvia, Derudas, Daniele, Belotti, Angelo, Zamagni, Elena, Paris, Laura, Pavone, Vincenzo, Mina, Roberto, Di Renzo, Nicola, Fazio, Francesca, Tarantini, Giuseppe, Pezzatti, Sara, Palumbo, Gaetano, Marcatti, Magda, Vincelli, Jolanda Donatella, Cafro, Anna Maria, Falcone, Antonietta Pia, Zambello, Renato, Conticello, Concetta, Mazza, Rita, Di Raimondo, Francesco, Pompa, Alessandra, Martino, Enrica Antonia, Morabito, Fortunato, Stefanoni, Paola, Barila, Gregorio, Farina, Francesca, Cartia, Claudio Salvatore, Casson, Andrea, Ferretti, Virginia, Fresi, Eleonora, Arcaini, Luca, Petrucci, Maria Teresa, and Gentile, Massimo

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results